CMS certification 053302
Children's Hosp of Los Angeles
4650 Sunset Blvd, Ms 108, Los Angeles, CA 90027
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
1,564 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 246 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 468 |
| Clinical | 71 |
| Psychologist | 63 |
| Pediatric Hematology-Oncology | 59 |
| Pediatric Emergency Medicine | 45 |
| Clinical Child & Adolescent | 33 |
| Neonatal-Perinatal Medicine | 32 |
| Occupational Therapist | 28 |
| Pediatric Gastroenterology | 27 |
| Pediatric Anesthesiology | 26 |
| Pediatric Cardiology | 26 |
| Anesthesiology | 25 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $6.7M
- 2020 $6.9M
- 2021 $9M
- 2022 $9.8M
- 2023 $6M
- 2024 $6.6M
- 2025 $6M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Grants | $225,725 | 6 |
| Speaking, teaching and other services | $133,055 | 5 |
| Medical devices and supplies on long-term loan | $12,480 | 11 |
| Space rental and facility fees | $6,500 | 5 |
| Debt forgiveness | $5,869 | 10 |
| Royalties and licensing fees | $3,000 | 3 |
| Charitable contributions | $1,325 | 12 |
| Honoraria | $489 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Mylan Inc. | $1.2M | 2 |
| Ultragenyx Pharmaceutical Inc. | $601,552 | 107 |
| Janssen Research & Development, LLC | $424,399 | 21 |
| Novo Nordisk AS | $272,514 | 38 |
| Eli Lilly and Company | $237,080 | 7 |
| Takeda Pharmaceuticals U.S.A., Inc. | $228,539 | 57 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $228,011 | 8 |
| Amgen Inc. | $202,538 | 5 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| Copyright License Agreement - Non-exclusive dated 8/10/2021 between CHLA and Mylan Mylan Inc. | $1.2M |
| Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene Janssen Research & Development, LLC | $273,144 |
| UX143-CL301 Ultragenyx Pharmaceutical Inc. | $233,399 |
| NN9924-4437 Novo Nordisk AS | $227,922 |
| UX023-CL401 Ultragenyx Pharmaceutical Inc. · NCT03651505 | $211,796 |
| wPhase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly… Amgen Inc. | $180,358 |
| A TACL PHASE 1/2 STUDY OF PO IXAZOMIB IN COMBINATION WITH VXLD CHEMOTHERAPY FOR CHILDHOOD RELAPSED OR REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA AND LYM… Takeda Pharmaceuticals U.S.A., Inc. | $173,706 |
| UX143-CL314 Ultragenyx Pharmaceutical Inc. | $156,357 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Children's Hosp of Los Angeles
Does Children's Hosp of Los Angeles have an emergency room?
Yes. CMS lists emergency services at Children's Hosp of Los Angeles.
Does Children's Hosp of Los Angeles receive money from drug and device companies?
Drug and device makers reported $6M in payments to Children's Hosp of Los Angeles for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.